201 related articles for article (PubMed ID: 17624533)
1. Positron emission tomography (PET) in the urooncological evaluation of the small pelvis.
Machtens S; Serth J; Meyer A; Kleinhorst C; Ommer KJ; Herbst U; Kieruij M; Boerner AR
World J Urol; 2007 Aug; 25(4):341-9. PubMed ID: 17624533
[TBL] [Abstract][Full Text] [Related]
2. [Positron emission tomography (PET) for diagnosis and monitoring of treatment for urological tumors].
Machtens S; Boerner AR; Hofmann M; Knapp WH; Jonas U
Urologe A; 2004 Nov; 43(11):1397-409. PubMed ID: 15502907
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography in urologic oncology.
Shvarts O; Han KR; Seltzer M; Pantuck AJ; Belldegrun AS
Cancer Control; 2002; 9(4):335-42. PubMed ID: 12228759
[TBL] [Abstract][Full Text] [Related]
4. Positron-emission tomography imaging in urological oncology: Current aspects and developments.
Rauscher I; Eiber M; Weber WA; Gschwend JE; Horn T; Maurer T
Int J Urol; 2018 Nov; 25(11):912-921. PubMed ID: 30103285
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and monitoring of urological tumors using positron emission tomography.
Hofer C; Kübler H; Hartung R; Breul J; Avril N
Eur Urol; 2001 Nov; 40(5):481-7. PubMed ID: 11752853
[TBL] [Abstract][Full Text] [Related]
6. Recent developments in urologic oncology: positron emission tomography molecular imaging.
Bouchelouche K; Oehr P
Curr Opin Oncol; 2008 May; 20(3):321-6. PubMed ID: 18391633
[TBL] [Abstract][Full Text] [Related]
7. Nuclear medicine studies of the prostate, testes, and bladder.
Jana S; Blaufox MD
Semin Nucl Med; 2006 Jan; 36(1):51-72. PubMed ID: 16356796
[TBL] [Abstract][Full Text] [Related]
8. Possible role of FDG-PET in the evaluation of urologic malignancies.
Bender H; Schomburg A; Albers P; Ruhlmann J; Biersack HJ
Anticancer Res; 1997; 17(3B):1655-60. PubMed ID: 9179213
[TBL] [Abstract][Full Text] [Related]
9. PET in prostate and bladder tumors.
Lee ST; Lawrentschuk N; Scott AM
Semin Nucl Med; 2012 Jul; 42(4):231-46. PubMed ID: 22681672
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors.
Tsatalpas P; Beuthien-Baumann B; Kropp J; Manseck A; Tiepolt C; Hakenberg OW; Burchert W; Franke WG; Wirth MP
Urol Int; 2002; 68(3):157-63. PubMed ID: 11919460
[TBL] [Abstract][Full Text] [Related]
11. [Value of positron emission tomography and computer tomography (PET/CT) for urologic malignancies].
Boujelbene N; Prior JO; Boubaker A; Azria D; Schaffer M; Gez E; Jichlinski P; Meuwly JY; Mirimanoff RO; Ozsahin M; Zouhair A
Cancer Radiother; 2011 Jul; 15(4):307-15. PubMed ID: 21507695
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography for urological tumours.
Hain SF; Maisey MN
BJU Int; 2003 Jul; 92(2):159-64. PubMed ID: 12823366
[TBL] [Abstract][Full Text] [Related]
13. PET-imaging in tumors of the reproductive trac.
Reinhardt MJ; Matthies A; Biersack HJ
Q J Nucl Med; 2002 Jun; 46(2):105-12. PubMed ID: 12114873
[TBL] [Abstract][Full Text] [Related]
14. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in urological cancers].
Bourguet P;
Bull Cancer; 2003 Feb; 90 Spec No():S80-7. PubMed ID: 12739339
[No Abstract] [Full Text] [Related]
15. Incidental Papillary Bladder Carcinoma on 18F-Fluoromethylcholine PET/CT Undertaken to Evaluate Prostate Malignancy.
Parekh A; Hagan I; Capaldi L; Lyburn I
Clin Nucl Med; 2017 Sep; 42(9):721-722. PubMed ID: 28682845
[TBL] [Abstract][Full Text] [Related]
16. Positron Emission Tomography and Computer Tomography (PET/CT) in Prostate, Bladder, and Testicular Cancers.
Zouhair A; Ozsahin M; Schaffer M; Albrecht S; Camus F; Jichlinski P; Mirimanoff RO; Bischof Delaloye A; Meuwly JY; Prior JO
Curr Med Chem; 2010; 17(23):2492-502. PubMed ID: 20491646
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography in urological oncology.
Hoh CK; Seltzer MA; Franklin J; deKernion JB; Phelps ME; Belldegrun A
J Urol; 1998 Feb; 159(2):347-56. PubMed ID: 9649238
[TBL] [Abstract][Full Text] [Related]
18. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
19. [Positron emission tomography. Introduction of a new procedure in diagnosis of urologic tumors and initial clinical results].
Bachor R; Kocher F; Gropengiesser F; Reske SN; Hautmann RE
Urologe A; 1995 Mar; 34(2):138-42. PubMed ID: 7754585
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography in uro-oncology.
Hain SF
Cancer Imaging; 2005 Jan; 5(1):1-7. PubMed ID: 16154810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
